Zeise M M, McDougall B W, Bartlett J D, Corliss D, Mitten L
School of Optometry, University of Alabama at Birmingham 35294-0010, USA.
J Am Optom Assoc. 1996 Nov;67(11):681-9.
Paremyd, consisting of a combination of 1.0 percent hydroxyamphetamine and 0.25 percent tropicamide, is a commercially available eyedrop used clinically for diagnostic mydriasis. This study sought to determine if one drop of Paremyd is equally effective and tolerable as the traditional combination of one drop each of 2.5 percent phenylephrine and 0.5 percent tropicamide.
A prospective, double-masked, randomized, cross-over study was conducted in 60 normal volunteers ranging from age 20 to 35 years (mean 24.3 years). Twenty-two subjects (36.7 percent) were male, and 32 subjects (53.3 percent) had brown irides. Pupil diameter, amplitude of accommodation, distance and near visual acuity, and subjective comfort of eyedrop instillation were assessed for 8 hours following drug instillation.
Significantly more subjects (p < 0.05) experienced adverse ocular symptoms with the tropicamide plus phenylephrine (TP) combination than with Paremyd (P). There was no statistically significant (p > 0.05) difference in mydriatic response between TP and P. During the first hour, however, TP and P demonstrated significant (p = 0.001) differences in cycloplegic effect.
Paremyd appears to be as effective a mydriatic as TP, but with greater comfort on instillation. Paremyd has less effect on accommodation.
派立明（Paremyd）由1.0%的羟苯丙胺和0.25%的托吡卡胺组成，是一种临床上用于诊断性散瞳的市售眼药水。本研究旨在确定一滴派立明与传统的2.5%去氧肾上腺素和0.5%托吡卡胺各一滴的组合是否具有同等的有效性和耐受性。
对60名年龄在20至35岁（平均24.3岁）的正常志愿者进行了一项前瞻性、双盲、随机、交叉研究。22名受试者（36.7%）为男性，32名受试者（53.3%）有棕色虹膜。在滴药后8小时评估瞳孔直径、调节幅度、远视力和近视力，以及滴眼药水时的主观舒适度。
与派立明（P）相比，托吡卡胺加去氧肾上腺素（TP）组合导致明显更多的受试者出现眼部不良反应（p < 0.05）。TP和P之间的散瞳反应没有统计学上的显著差异（p > 0.05）。然而，在第一个小时内，TP和P在睫状肌麻痹作用上表现出显著差异（p = 0.001）。
派立明似乎与TP一样是有效的散瞳剂，但滴入时更舒适。派立明对调节的影响较小。
